Biotechnology - Mergers & Acquisitions, Financial


Popular Filters

1 to 25 of 33 results

Low dollar tipped to stimulate biotech investment in Australia


Analyst commentary suggests the devaluation of the Australian dollar during 2014, has left biotech in…

ActinogenAustraliaBenitec BiopharmaBiotechnologyFinancialMergers & AcquisitionsSirtex Medical

Valneva and BliNK Therapeutics launch new biotech company

Valneva and BliNK Therapeutics launch new biotech company


France-based biotech firm Valneva and privately-held UK company BliNK Therapeutics have created a private…

BiotechnologyBliNK BiomedicalBliNK TherapeuticsFinancialFranceMergers & AcquisitionsUKValneva

Strides Arcolab makes strategic investment in Oncobiologics

Strides Arcolab makes strategic investment in Oncobiologics


India’s Strides Arcolab has made a series of strategic investments in Oncobiologics, a privately held…

BiosimilarsBiotechnologyFinancialIndiaMergers & AcquisitionsOncobiologicsStrides Arcolab

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story


A biotech company’s dream 14-year journey from small start-up to an $886 million takeover bid provided…

Asia-PacificAstex PharmaceuticalsBiotechnologyFinancialInterviewsMergers & AcquisitionsOtsukaUKUSA

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring


US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Aphios spins off Amylon to develop novel Alzheimer’s disease drug


US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

Osiris to sell culture-expanded MSCs business including Prochymal


USA-based Osiris Therapeutics has entered into an agreement with a wholly-owned subsidiary of Mesoblast…

BiotechnologyFinancialMergers & AcquisitionsMesoblastOsiris TherapeuticsProchymal

July a strong month for life sciences IPOs and M&A


The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

Valneva to sell French CMO operations to India's Biological E


Biotech firm Valneva (Euronext: VLA), the company recently created through the merger of France's Vivalis…

Biological E LtdBiotechnologyEB66FinancialMergers & AcquisitionsProductionValneva

Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill


A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

Biotech industry has "implementation gap" around demonstrating the value of products under development


Ernst & Young's annual biotech report shows strong performance by major players but a challenging environment…

BiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaResearch

Two life sciences IPOs and strengthening markets offer encouragement to Biotech sector


Two companies focused on infectious disease successfully completed initial public offerings (IPOs) in…

BiotechnologyFinancialLicensingMergers & Acquisitions

Elan to unlock benefits for shareholders from Tysabri deal


The board of Ireland-based drugmaker Elan Corp (NYSE:ELN) has approved the decision to initiate a unique…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Bone Therapeutics invests in state-of-the-art cell therapy manufacturing facility and SCTS


Belgium-based biopharmaceutical company Bone Therapeutics, focused on innovative cell therapy products…

BiotechnologyBone TherapeuticsEuropeFinancialMergers & AcquisitionsPreobProductionSkeletal Cell Therapy Support

Briefs: Sanofi to up stake in Regeneron; Bayer files for riociguat approval


US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares rise 4.8% to $173.84 in early trading…

BayerBiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegeneronRegulationRespiratory and PulmonaryriociguatSanofi

Sun Pharma gives up fight to take full control of Taro; Angel Biotech in administration


Israel-based Taro Pharmaceutical Industries (Pink Sheets: TAROF) and Indian drugmaker Sun Pharmaceutical…

Angel BiomedicalAngel BiotechnologyBiotechnologyFinancialMergers & AcquisitionsPharmaceuticalSun Pharmaceutical IndustriesTaro Pharmaceuticals

Elan sells its Tysabri rights to Biogen; posts 2012 financials


Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

Zoetis IPO caps strong month for life sciences financings, says Burrill & Co


Life sciences financing activity got a strong start in the New Year as companies raised $10.3 billion…

AllerganBiotechnologyFinancialMAP PharmaceuticalsMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer's Zoetis spin-off could raise $12 billion; BGI-Shenzhen updates on Complete Genomics deal


Pfizer (NYSE: PFE), the world's largest drugmaker by sales, which has previously said it is spinning…

BGI-ShenzhenBiotechnologyComplete GenomicsFinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

Big pharma will increasingly tap M&A to close $100 billion growth gap


Big pharma companies are facing a widening "growth gap" that will increase pressure to drive growth through…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

Geron signs tentative deal with BioTime on stem cell assets


A year after announcing its decision to exit stem cell therapy, the USA's Geron Corp (Nasdaq: GERN) has…

BiotechnologyBioTimeFinancialGeron CorpMergers & Acquisitions

M&A briefs: GlaxoSmithKline/Response Genetics; Bayer/Teva unit


USA-based Response Genetics (Nasdaq: RGDX) last week entered into a purchase agreement with UK pharma…

BayerBiotechnologyFinancialGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalResponse GeneticsTeva Pharmaceutical Industries

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal


Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Pharmaceutical supply chain in Japan sees squeezed margins


Pressures felt in Japan as a result of the country's aging population, drug price revisions and patent…

Asia-PacificBiotechnologyFinancialMarkets & MarketingMergers & AcquisitionsPharmaceuticalPricing

1 to 25 of 33 results

Back to top